🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

444 results for “Ology” Clear

  1. Dexmedetomidine injection

    Sana Biotechnology

    Post Spinal Shivering

    phase 2 small molecule active

    1 trial

  2. Diamyd

    Ology Bioservices Ireland LTD

    Latent Autoimmune Diabetes in Adults (LADA)

    phase 2 small molecule active

    1 trial

  3. Dostarlimab

    LIXTE BIOTECHNOLOGY HOLDINGS, INC.

    Ovarian Clear Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Dupilumab

    Coherus Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  5. Etrinabdione oral solution

    Ology Bioservices Ireland LTD

    Peripheral Arterial Disease

    phase 2 small molecule active

    1 trial

  6. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Microsatellite Stable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  7. Evorpacept (ALX148)

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer, Metastatic

    phase 2 small molecule active

    1 trial

  8. FOLFIRI regimen

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  9. Fluorouracil Injection 25 mg/ml, solution for injection, Oncofolic 50 mg/ml, Injektions-/Infusionslösung, Irinotecan Hydrochloride 20 mg/mL concentrate for solution for infusion

    Ology Bioservices Ireland LTD

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  10. Fulvestrant STADA 250 mg injekcinis tirpalas užpildytame švirkšte, Alisertib Enteric-Coated Tablets, Exemestane SanoSwiss 25 mg plėvele dengtos tabletės, Anastrozole Accord 1 mg plėvele dengtos tabletės, Letrozole SanoSwiss 2,5 mg plėvele dengtos tabletės, Tamoxifen EBEWE 20 mg tabletės

    PUMA BIOTECHNOLOGY, INC.

    Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

    phase 2 small molecule active

    1 trial

  11. Functional Precision Oncology

    United Therapeutics Europe Ltd

    Breast Cancer Recurrent

    phase 2 other active

    1 trial

  12. GEMCITABINE

    Ology Bioservices Ireland LTD

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    phase 2 small molecule active

    1 trial

  13. HCQ01

    Sana Biotechnology

    2019 Novel Coronavirus

    phase 2 small molecule active

    2 trials

  14. HEPCLUDEX 2 mg powder for solution for injection, VIR-2218, VIR-3434

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  15. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  16. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  17. HKI-272

    PUMA BIOTECHNOLOGY, INC.

    Advanced Breast Cancer

    phase 2 small molecule completed

    2 trials

  18. Hydrocortisone acetate and lidocaine hydrochloride

    CITIUS ONCOLOGY, INC.

    Hemorrhoids

    phase 2 small molecule completed

    1 trial

  19. Hydroxyurea

    Sana Biotechnology

    Thalassemia, Beta

    phase 2 small molecule active

    1 trial

  20. Iclusig 15 mg film-coated tablets, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., Imatinib TAD 400 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  21. Infigratinib

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial

  22. Infigratinib

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  23. Infigratinib 0.016 mg/kg

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule completed

    1 trial

  24. Infigratinib is provided as a single dose of minitablets for oral administration

    BridgeBio Oncology Therapeutics

    Achondroplasia

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources